{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:21:59Z","timestamp":1790882519340,"version":"4.1.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002997","name":"Dutch Kidney Foundation","doi-asserted-by":"publisher","award":["CP10.12"],"award-info":[{"award-number":["CP10.12"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002997","name":"Dutch Kidney Foundation","doi-asserted-by":"publisher","award":["CP15.01"],"award-info":[{"award-number":["CP15.01"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dutch government","award":["LSHM15018"],"award-info":[{"award-number":["LSHM15018"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,26]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Dysregulated energy metabolism is a recently discovered key feature of autosomal dominant polycystic kidney disease (ADPKD). Cystic cells depend on glucose and are poorly able to use other energy sources such as ketone bodies. Raising ketone body concentration reduced disease progression in animal models of polycystic kidney diseases. Therefore, we hypothesized that higher endogenous plasma beta-hydroxybutyrate (BHB) concentrations are associated with reduced disease progression in patients with ADPKD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analyzed data from 670 patients with ADPKD participating in the Developing Intervention Strategies to Halt Progression of ADPKD (DIPAK) cohort, a multi-center prospective observational cohort study. BHB was measured at baseline using nuclear magnetic resonance spectroscopy. Participants were excluded if they had type 2 diabetes, were using disease-modifying drugs (e.g. tolvaptan, somatostatin analogs), were not fasting or had missing BHB levels, leaving 521 participants for the analyses. Linear regression analyses were used to study cross-sectional associations and linear mixed-effect modeling for longitudinal associations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the participants, 61% were female, with an age of 47.3\u00a0\u00b1\u00a011.8 years, a height-adjusted total kidney volume (htTKV) of 834 [interquartile range (IQR) 495\u20131327] mL\/m and an estimated glomerular filtration rate (eGFR) of 63.3\u00a0\u00b1\u00a028.9\u00a0mL\/min\/1.73 m2. The median concentration of BHB was 94 (IQR 68\u2013147) \u00b5mol\/L. Cross-sectionally, BHB was associated neither with eGFR nor with htTKV. Longitudinally, BHB was positively associated with eGFR slope {B\u00a0=\u00a00.35\u00a0mL\/min\/1.73 m2 [95% confidence interval (CI) 0.09 to 0.61], P\u00a0=\u00a0.007}, but not with kidney growth. After adjustment for potential confounders, every doubling in BHB concentration was associated with an improvement in the annual rate of eGFR by 0.33\u00a0mL\/min\/1.73 m2 (95% CI 0.09 to 0.57, P\u00a0=\u00a0.008).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These observational analyses support the hypothesis that interventions that raise BHB concentration could reduce the rate of kidney function decline in patients with ADPKD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfad239","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T15:05:52Z","timestamp":1700060752000},"page":"838-847","source":"Crossref","is-referenced-by-count":18,"title":["Higher beta-hydroxybutyrate ketone levels associated with a slower kidney function decline in ADPKD"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1780-4899","authenticated-orcid":false,"given":"Martine G E","family":"Knol","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen , Groningen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bais","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen , Groningen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1376-9727","authenticated-orcid":false,"given":"Paul","family":"Geertsema","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen , Groningen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margery A","family":"Connelly","sequence":"additional","affiliation":[{"name":"Labcorp, Morrisville , NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan J L","family":"Bakker","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen , Groningen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3223-0906","authenticated-orcid":false,"given":"Ron T","family":"Gansevoort","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen , Groningen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maatje D A","family":"van Gastel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen , Groningen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the DIPAK Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J P H","family":"Drenth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J W","family":"de Fijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D J M","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E J","family":"Hoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Nijenhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"2024042523510752000_bib1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"key":"2024042523510752000_bib2","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/ki.2014.120","article-title":"Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease","volume":"86","author":"Spithoven","year":"2014","journal-title":"Kidney Int"},{"key":"2024042523510752000_bib3","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s40265-022-01745-9","article-title":"Drugs in clinical development to treat autosomal dominant polycystic kidney disease","volume":"82","author":"Bais","year":"2022","journal-title":"Drugs"},{"key":"2024042523510752000_bib4","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.3092","article-title":"Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy","volume":"19","author":"Rowe","year":"2013","journal-title":"Nat Med"},{"key":"2024042523510752000_bib5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.cmet.2016.12.022","article-title":"Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics","volume":"25","author":"Puchalska","year":"2017","journal-title":"Cell Metab"},{"key":"2024042523510752000_bib6","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.cmet.2019.09.012","article-title":"Ketosis ameliorates renal cyst growth in polycystic kidney disease","volume":"30","author":"Torres","year":"2019","journal-title":"Cell Metab"},{"key":"2024042523510752000_bib7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1681\/ASN.2015020132","article-title":"Food restriction ameliorates the development of polycystic kidney disease","volume":"27","author":"Warner","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2024042523510752000_bib8","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024042523510752000_bib9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nat Med"},{"key":"2024042523510752000_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.1227166","article-title":"Suppression of oxidative stress by \u03b2-hydroxybutyrate, an endogenous histone deacetylase inhibitor","volume":"339","author":"Shimazu","year":"2013","journal-title":"Science"},{"key":"2024042523510752000_bib11","doi-asserted-by":"crossref","first-page":"100009","DOI":"10.1016\/j.arres.2021.100009","article-title":"Ketone bodies for kidney injury and disease","volume":"2","author":"Rojas-Morales","year":"2021","journal-title":"Adv Redox Res"},{"key":"2024042523510752000_bib12","doi-asserted-by":"crossref","first-page":"e12699","DOI":"10.1111\/acel.12699","article-title":"Ketone body 3-hydroxybutyrate mimics calorie restriction via the Nrf2 activator, fumarate, in the retina","volume":"17","author":"Izuta","year":"2018","journal-title":"Aging Cell"},{"key":"2024042523510752000_bib13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/jcm9020321","article-title":"Ketone bodies are mildly elevated in subjects with type 2 diabetes mellitus and are inversely associated with insulin resistance as measured by the lipoprotein insulin resistance index","volume":"9","author":"Garcia","year":"2020","journal-title":"J Clin Med"},{"key":"2024042523510752000_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2024042523510752000_bib15","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1093\/ckj\/sfab112","article-title":"The association of glucagon with disease severity and progression in patients with autosomal dominant polycystic kidney disease: an observational cohort study","volume":"14","author":"Knol","year":"2021","journal-title":"Clin Kidney J"},{"key":"2024042523510752000_bib16","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2024042523510752000_bib17","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1161\/HYPERTENSIONAHA.119.13735","article-title":"Concentration of branched-chain amino acids is a strong risk marker for incident hypertension","volume":"74","author":"Flores-Guerrero","year":"2019","journal-title":"Hypertension"},{"key":"2024042523510752000_bib18","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1681\/ASN.2018090902","article-title":"Automatic measurement of kidney and liver volumes from MR Images of patients affected by autosomal dominant polycystic kidney disease","volume":"30","author":"van Gastel","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2024042523510752000_bib19","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s10278-017-9978-1","article-title":"Performance of an artificial multi-observer deep neural network for fully automated segmentation of polycystic kidneys","volume":"30","author":"Kline","year":"2017","journal-title":"J Digit Imaging"},{"key":"2024042523510752000_bib20","first-page":"1857","article-title":"Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial","volume":"32","author":"Irazabal","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2024042523510752000_bib21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/ki.1985.10","article-title":"A method for estimating nitrogen intake of patients with chronic renal failure","volume":"27","author":"Maroni","year":"1985","journal-title":"Kidney Int"},{"key":"2024042523510752000_bib22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clinbiochem.2014.07.015","article-title":"NMR measurement of LDL particle number using the Vantera\u00ae Clinical Analyzer","volume":"47","author":"Matyus","year":"2014","journal-title":"Clin Biochem"},{"key":"2024042523510752000_bib23","first-page":"6","article-title":"The power of outliers (and why researchers should ALWAYS check for them)","volume":"9","author":"Osborne","year":"2004","journal-title":"PARE"},{"key":"2024042523510752000_bib24","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1161\/01.ATV.0000092326.00725.ED","article-title":"Gender differences in postprandial ketone bodies in normolipidemic subjects and in untreated patients with familial combined hyperlipidemia","volume":"23","author":"Halkes","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2024042523510752000_bib25","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1210\/jcem-46-3-414","article-title":"Sex variations in free fatty acids and ketones during fasting: evidence for a role of glucagon","volume":"46","author":"Merimee","year":"1978","journal-title":"J Clin Endocrinol Metab"},{"key":"2024042523510752000_bib26","article-title":"Ketone body metabolism declines with age in mice in a sex-dependent manner","author":"Eap","year":"2022","journal-title":"biorxiv"},{"key":"2024042523510752000_bib27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.celrep.2018.09.058","article-title":"Salt-responsive metabolite, \u03b2-hydroxybutyrate, attenuates hypertension","volume":"25","author":"Chakraborty","year":"2018","journal-title":"Cell Rep"},{"key":"2024042523510752000_bib28","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1172\/JCI106395","article-title":"Effect of ethanol on ketone metabolism","volume":"49","author":"Lef\u00e8vre","year":"1970","journal-title":"J Clin Invest"},{"key":"2024042523510752000_bib29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12199-011-0231-0","article-title":"Age-related effects of fasting on ketone body production during lipolysis in rats","volume":"17","author":"Higashino-Matsui","year":"2012","journal-title":"Environ Health Prev Med"},{"key":"2024042523510752000_bib30","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.metabol.2005.05.023","article-title":"Ketone body metabolism in lean and obese women","volume":"54","author":"Vice","year":"2005","journal-title":"Metabolism"},{"key":"2024042523510752000_bib31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-2007-1003241","article-title":"Suppressive effect of vasopressin on ketosis in diabetic rats","volume":"24","author":"Harano","year":"1992","journal-title":"Horm and Metab Res"},{"key":"2024042523510752000_bib32","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.kint.2018.11.034","article-title":"\u03b2-hydroxybutyrate attenuates renal ischemia-reperfusion injury through its anti-pyroptotic effects","volume":"95","author":"Tajima","year":"2019","journal-title":"Kidney Int"},{"key":"2024042523510752000_bib33","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bbrc.2014.04.074","article-title":"Protective effects of exogenous \u03b2-hydroxybutyrate on paraquat toxicity in rat kidney","volume":"447","author":"Wei","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"2024042523510752000_bib34","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/ckj\/sfab162","article-title":"Ketogenic dietary interventions in autosomal dominant polycystic kidney disease\u2014a retrospective case series study: first insights into feasibility, safety and effects","volume":"15","author":"Strubl","year":"2022","journal-title":"Clin Kidney J"},{"key":"2024042523510752000_bib35","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1093\/ndt\/gfac311","article-title":"RESET-PKD: a pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease","volume":"38","author":"Oehm","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2024042523510752000_bib36","volume-title":"KETO-ADPKD: a randomized, controlled trial on ketogenic dietary interventions in autosomal dominant polycystic kidney disease","author":"Cukoski","year":"2022"},{"key":"2024042523510752000_bib37","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2009040421","article-title":"Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1","volume":"21","author":"Shillingford","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2024042523510752000_bib38","doi-asserted-by":"crossref","first-page":"109495","DOI":"10.1016\/j.cellsig.2019.109495","article-title":"Metabolic reprogramming and the role of mitochondria in polycystic kidney disease","volume":"67","author":"Podrini","year":"2020","journal-title":"Cell Signal"},{"key":"2024042523510752000_bib39","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024042523510752000_bib40","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ajkd.2012.08.038","article-title":"Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort","volume":"61","author":"Boertien","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2024042523510752000_bib41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1042\/bj2120231","article-title":"Metabolic effects of vasopressin infusion in the starved rat. Reversal of ketonaemia","volume":"212","author":"Rofe","year":"1983","journal-title":"Biochem J"},{"key":"2024042523510752000_bib42","doi-asserted-by":"crossref","first-page":"e72919","DOI":"10.7554\/eLife.72919","article-title":"Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes","volume":"10","author":"Kim","year":"2021","journal-title":"eLife"},{"key":"2024042523510752000_bib43","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2265.1985.tb00145.x","article-title":"The effect of vasopressin infusion on glucose metabolism in man","volume":"22","author":"Spruce","year":"1985","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfad239\/54153439\/gfad239.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/5\/838\/57332449\/gfad239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/5\/838\/57332449\/gfad239.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T23:51:41Z","timestamp":1714089101000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/39\/5\/838\/7424998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,11,16]]},"published-print":{"date-parts":[[2024,4,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfad239","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2023,11,16]]}}}